Search by Drug Name or NDC

    NDC 70257-0416-87 Lyvispah 20 mg/1 Details

    Lyvispah 20 mg/1

    Lyvispah is a ORAL GRANULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Saol Therapeutics Inc. The primary component is BACLOFEN.

    Product Information

    NDC 70257-0416
    Product ID 70257-416_4057e10f-332f-48e1-8c97-e80b93331add
    Associated GPIs 75100010003030
    GCN Sequence Number 082878
    GCN Sequence Number Description baclofen GRAN PACK 20 MG ORAL
    HIC3 H6H
    HIC3 Description SKELETAL MUSCLE RELAXANTS
    GCN 51652
    HICL Sequence Number 001949
    HICL Sequence Number Description BACLOFEN
    Brand/Generic Brand
    Proprietary Name Lyvispah
    Proprietary Name Suffix n/a
    Non-Proprietary Name baclofen
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form GRANULE
    Route ORAL
    Active Ingredient Strength 20
    Active Ingredient Units mg/1
    Substance Name BACLOFEN
    Labeler Name Saol Therapeutics Inc
    Pharmaceutical Class GABA A Agonists [MoA], GABA B Agonists [MoA], gamma-Aminobutyric Acid-ergic Agonist [EPC]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA215422
    Listing Certified Through 2024-12-31

    Package

    NDC 70257-0416-87 (70257041687)

    NDC Package Code 70257-416-87
    Billing NDC 70257041687
    Package 90 PACKET in 1 BOTTLE, UNIT-DOSE (70257-416-87) / 1 GRANULE in 1 PACKET
    Marketing Start Date 2021-11-22
    NDC Exclude Flag N
    Pricing Information N/A